Human Papillomavirus Vaccine Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 7.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Human Papillomavirus Vaccine Market Analysis
The human papillomavirus (HPV) vaccine market is expected to register a CAGR of nearly 7.5% during the forecast period.
As the pandemic hit, the screening and diagnosis of non-emergency diseases were postponed worldwide, which has impacted the studied market. As per a research study published in March 2021 in PubMed, 74% of the total respondent laboratories globally experienced a supply shortage for HPV tests for cervical cancer screening. Therefore, there was a reduction in cervical cancer and other related cancer screening, ultimately reducing the demand for the HPV vaccine during the pandemic. Furthermore, a research study published in January 2023 in Vaccines indicated that a 75% reduction in HPV vaccination coverage was observed in the United States during the initial phase of the pandemic as compared to the previous year. Hence, owing to the factors mentioned above, the COVID-19 pandemic significantly impacted the market studied. However, with the COVID-19 cases in control, the market regained its pre-pandemic nature in terms of demand for HPV vaccines. Furthermore, due to the increasing initiatives by government & private organizations for early screening & vaccination and approval of new HPV vaccines, the market is believed to witness significant growth over the forecast period.
The rising prevalence of HPV-related diseases such as cervical cancer, anal cancer, and genital warts is expected to boost the demand for HPV vaccines significantly. For instance, as per the India, HPV and Related Cancers, 2023 report, cervical cancer ranks as the 2nd most frequent cancer among women in India and the 2nd most frequent cancer among women between 15 and 44. As per the same source, 123,907 women are diagnosed with cervical cancer in India each year. Therefore, the high burden of cervical cancer is expected to boost the demand for HPV vaccine during the forecast period.
The initiatives by the government to fund the HPV vaccines and rising screening and immunization programs are expected to boost the market growth. For instance, according to an article published in January 2023 in Vaccines Journal, the HPV vaccine is fully funded for children aged 11-14 years old and for 15-26-year-old females in Switzerland. Also, in March 2022, in Greece, a gender-neutral HPV vaccination program was launched.
Furthermore, in January 2021, the United States Department of Health and Human Services launched the "HPV VAX NOW" campaign to increase HPV vaccination rates among young adults aged 18-26 years. Also, in November 2021, Saudi Arabia launched a human papillomavirus infection program for young girls aged 9-13 years to prevent them from developing cervical cancer. This is expected to increase the development of HPV-cervical cancer vaccines hence bolstering the market growth.
Therefore, the factors such as the high burden of cervical cancer and rising screening and immunization programs, and launches of vaccines, the studied market is expected to witness growth during the forecast period. However, stringent regulation is likely to hinder market growth over the forecast period.
Human Papillomavirus Vaccine Market Trends
Cervical Cancer Segment is Expected to Hold the Significant Market Share Over the Forecast Period
The cervical cancer segment is expected to witness healthy growth in the market during the forecast period. Nearly all instances of cervical cancer are caused by human papillomavirus (HPV). The segment is expected to grow during the forecast period due to the growing burden of cervical cancer, supported by government initiatives for early screening, vaccination, and vaccine approval.
According to the American Cancer Society (ACS) 2023 report, an estimated 13,960 new cases of cervical cancer are predicted to be diagnosed in the United States in 2023. Moreover, as per Japan Human Papillomavirus, Fact Sheet 2023, every year, 12,785 women are diagnosed with cervical cancer, with an incidence of HPV-related cervical cancer of 19.8 in 2023. Therefore, the high burden of cervical cancer will boost the demand for developing innovative vaccines, propelling market growth.
Furthermore, the rising screening and awareness initiatives increase the diagnoses, further expected to boost the market growth. For instance, in February 2022, the Department of Health and Social Care (DHSC), with the support of the National Health Service (NHS), launched a new national cervical screening campaign to boost the number of eligible candidates to attend their cervical screening in England. The increased screening is projected to boost the demand for the HPV vaccine to provide protection against the high-risk HPV types associated with cervical cancer, thereby propelling the segment's growth.
The rising research and development to launch innovative vaccines is projected to boost the market growth. For instance, in September 2022, the Government of India launched the Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer in India, which was developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT). As per the SII, the vaccine would cost around USD 2.5 - USD 5 (INR 200-400) per dose, which is significantly lower compared to other parts of the world.
Thus, owing to the increasing cases of cervical cancer, rising cervical cancer screening, and growing vaccine launches, the segment is expected to witness high growth over the forecast period.
North America is Expected to Hold Significant Market Share Over the Forecast Period
North America is expected to hold a significant market share of the HPV vaccine market owing to better healthcare infrastructure and the high burden of Cervical Cancer and other HPV-related cancers. In addition, the increased presence of market players and strategic initiatives also drive the market growth during the forecast period.
According to the American Cancer Society 2022 report, 9,440 new anal cancer were diagnosed in the United States in 2022. Moreover, per the Canadian Cancer Society, 1,450 Canadian women were diagnosed with cervical cancer in 2022. Therefore, the high burden of such cancers is expected to boost the growth of the studied market in the region during the forecast period.
In addition, according to an article published in February 2023 in the Human Vaccine and Immunotherapeutic Journal, HPV vaccination in the United States can start at age nine and last until age 26. Also, approximately 77% of 13 to 17-year-old teenagers have received one or more doses of the HPV vaccine, and nearly 62% have finished the entire series. The high coverage for the HPV vaccine and early screening initiatives in the region boost the demand for HPV vaccines during the forecast period.
Furthermore, the strategic initiatives by market players, such as launches and approvals, partnerships, and collaborations, also accelerate the market growth. For instance, in April 2022, Merck Canada received Health Canada's approval for an expanded indication of GARDASIL 9 ((Human Papillomavirus 9-valent Vaccine, Recombinant) in individuals 9 through 45 years of age to prevent infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
Therefore, factors such as the growing cancer burden and vaccine launches and approvals are expected to boost the market growth in North America during the forecast period.
Human Papillomavirus Vaccine Industry Overview
The market studied is a consolidated market owing to the presence of a few major market players. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including Merck & Co., Inc., GSK plc, Serum Institute of India Pvt. Ltd., and Wantai BioPharm among others.
Human Papillomavirus Vaccine Market Leaders
-
Serum Institute of India Pvt. Ltd.
-
Wantai BioPharm
-
INOVIO Pharmaceuticals
-
Merck & Co., Inc.
-
GSK plc.
*Disclaimer: Major Players sorted in no particular order
Human Papillomavirus Vaccine Market News
- March 2023: CAPED and Roche Diagnostics signed a Memorandum of Understanding (MoU) with the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization that promotes cancer awareness, prevention, and early detection. The partnership aimed to launch a Cervical Cancer screening program in India.
- February 2023: Australia switched from two doses to a single dose of the Gardasil 9 human papillomavirus vaccine for routine immunization of young people under the National Immunisation Program.
Human Papillomavirus Vaccine Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Defination
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Approval of New HPV Vaccines
4.2.2 Increasing Initiatives by Government & Private Organizations for Early Screening & Vaccination
4.3 Market Restraints
4.3.1 Stringent Regulation
4.4 Porter's Five Force Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Type
5.1.1 Bivalent
5.1.2 Quadrivalent
5.1.3 Nonavalent
5.2 By Indication
5.2.1 Cervical Cancer
5.2.2 Anal Cancer
5.2.3 Penile Cancer
5.2.4 Oropharyngeal Cancer
5.2.5 Genital Warts
5.2.6 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bharat Biotech
6.1.2 Merck & Co., Inc.,
6.1.3 GSK plc.
6.1.4 Serum Institute of India Pvt. Ltd.
6.1.5 Wantai BioPharm
6.1.6 INOVIO Pharmaceuticals
6.1.7 Walvax Biotechnology Co., Ltd
6.1.8 Novartis AG
6.1.9 Inovio pharmaceuticals
6.1.10 AstraZeneca
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Human Papillomavirus Vaccine Industry Segmentation
As per the scope of this report, human papillomavirus vaccines are vaccines that are utilized to prevent HPV infection. HPV is a group of more than 100 viruses, of which 13 can cause cancer, and nearly all cases of cervical cancer are attributed to HPV. The human papillomavirus vaccine market is segmented by type (bivalent, quadrivalent, nonavalent), indication (cervical cancer, anal cancer, penile cancer, oropharyngeal cancer, genital warts, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Type | |
| Bivalent | |
| Quadrivalent | |
| Nonavalent |
| By Indication | |
| Cervical Cancer | |
| Anal Cancer | |
| Penile Cancer | |
| Oropharyngeal Cancer | |
| Genital Warts | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Human Papillomavirus Vaccine Market Research FAQs
What is the current Global Human Papillomavirus Vaccine Market size?
The Global Human Papillomavirus Vaccine Market is projected to register a CAGR of 7.5% during the forecast period (2024-2029)
Who are the key players in Global Human Papillomavirus Vaccine Market?
Serum Institute of India Pvt. Ltd., Wantai BioPharm, INOVIO Pharmaceuticals, Merck & Co., Inc. and GSK plc. are the major companies operating in the Global Human Papillomavirus Vaccine Market.
Which is the fastest growing region in Global Human Papillomavirus Vaccine Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Human Papillomavirus Vaccine Market?
In 2024, the North America accounts for the largest market share in Global Human Papillomavirus Vaccine Market.
What years does this Global Human Papillomavirus Vaccine Market cover?
The report covers the Global Human Papillomavirus Vaccine Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Human Papillomavirus Vaccine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
How can companies compete with established players in the HPV Vaccine Market?
Companies can compete with established players in the HPV Vaccine Market through a) Innovation b) Focusing on specific market needs c) Strategic partnerships
Human Papillomavirus Vaccines Industry Report
The Human Papillomavirus Vaccine Market is witnessing substantial growth, driven by the increasing prevalence of HPV-related diseases such as cervical cancer, anal cancer, and genital warts. This market is categorized based on type, disease indication, and industry vertical, offering vaccines like bivalent, quadrivalent, and nonavalent, each targeting different virus strains. Cervical cancer dominates the disease indication segment, especially in underdeveloped regions. Key industry verticals include public-private partnerships, government bodies, and healthcare providers, with significant market expansion seen across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific, in particular, is experiencing rapid growth due to enhanced healthcare investments and vaccine development initiatives. Market dynamics are further propelled by both government and private sector efforts to promote early screening and vaccination, as well as the introduction of new vaccine formulations aimed at improving efficacy and accessibility. For detailed statistics, market share, size, revenue growth rate, and a forecast outlook of the Human Papillomavirus Vaccines, refer to Mordor Intelligenceā¢ Industry Reports. Enhance your understanding by downloading a free report PDF sample from their analysis.
